Mesoblast Chief Medical Officer Dr Fred Grossman said: “The extensive body of safety and efficacy data generated to date using remestemcel-L in children with graft versus host disease suggest that our cellular therapy could provide a clinically important therapeutic benefit in MIS-C patients, especially if the heart is involved as a target organ for inflammation. Use of remestemcel-L in children with COVID-19 builds on and extends the potential application of this cell therapy in COVID-19 cytokine storm beyond the most severe adults with acute respiratory distress syndrome.”
So exciting!
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19, page-3
-
- There are more pages in this discussion • 246 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.66 |
Change
0.010(0.61%) |
Mkt cap ! $2.114B | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.64 | $5.790M | 3.482M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 460 | $1.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.66 | 67181 | 6 |
View Market Depth
| Last trade - 16.10pm 11/07/2025 (20 minute delay) ? |
| MSB (ASX) Chart |